Your browser is no longer supported. Please, upgrade your browser.
CORT Corcept Therapeutics Incorporated monthly Stock Chart
Corcept Therapeutics Incorporated
Index- P/E19.17 EPS (ttm)0.93 Insider Own0.30% Shs Outstand115.01M Perf Week-0.83%
Market Cap2.05B Forward P/E23.55 EPS next Y0.76 Insider Trans0.36% Shs Float104.24M Perf Month6.41%
Income114.10M PEG- EPS next Q0.21 Inst Own79.30% Short Float18.26% Perf Quarter7.18%
Sales351.20M P/S5.84 EPS this Y29.10% Inst Trans1.08% Short Ratio6.73 Perf Half Y32.42%
Book/sh3.94 P/B4.53 EPS next Y-11.66% ROA26.50% Target Price17.75 Perf Year26.24%
Cash/sh3.53 P/C5.06 EPS next 5Y- ROE29.10% 52W Range9.70 - 23.48 Perf YTD47.52%
Dividend- P/FCF11.88 EPS past 5Y34.90% ROI24.00% 52W High-23.98% Beta0.78
Dividend %- Quick Ratio10.30 Sales past 5Y63.10% Gross Margin98.30% 52W Low84.02% ATR0.62
Employees206 Current Ratio10.40 Sales Q/Q22.50% Oper. Margin40.10% RSI (14)57.70 Volatility3.37% 3.30%
OptionableYes Debt/Eq0.00 EPS Q/Q38.70% Profit Margin32.50% Rel Volume0.18 Prev Close17.76
ShortableYes LT Debt/Eq0.00 EarningsAug 04 AMC Payout0.00% Avg Volume2.83M Price17.85
Recom2.50 SMA200.44% SMA507.43% SMA20023.17% Volume495,681 Change0.51%
Aug-05-20Downgrade Jefferies Buy → Hold $16
Sep-24-19Initiated Jefferies Buy $20
Sep-06-19Initiated H.C. Wainwright Buy $18
Feb-04-19Downgrade B. Riley FBR Buy → Neutral $22 → $12
Aug-10-18Reiterated Stifel Hold $20 → $11
May-31-18Downgrade Stifel Buy → Hold $20
Mar-09-18Initiated B. Riley FBR, Inc. Buy $30
Aug-31-17Initiated Stifel Buy $20
Feb-02-17Initiated Ladenburg Thalmann Buy $14
Apr-21-15Initiated FBR Capital Outperform $12
Jan-13-14Downgrade Stifel Buy → Hold
Aug-09-13Downgrade Ladenburg Thalmann Buy → Neutral $3.30
Aug-09-13Downgrade Janney Buy → Neutral
Feb-21-12Reiterated JMP Securities Mkt Outperform $9 → $11
Jan-06-10Upgrade Ladenburg Thalmann Neutral → Buy $4
Jul-17-08Initiated Rodman & Renshaw Mkt Outperform $8
Jun-21-07Upgrade Punk, Ziegel & Co Mkt Perform → Accumulate
Oct-16-20 08:00AM  
Oct-07-20 10:26AM  
Oct-05-20 12:46PM  
Sep-29-20 09:00AM  
Sep-24-20 07:10AM  
Sep-18-20 07:26AM  
Sep-17-20 10:56AM  
Sep-10-20 08:30AM  
Sep-08-20 04:34AM  
Sep-04-20 11:41AM  
Sep-03-20 11:31AM  
Sep-01-20 09:34AM  
Aug-05-20 05:56PM  
Aug-04-20 04:05PM  
Aug-03-20 06:27PM  
Jul-28-20 04:05PM  
Jul-23-20 08:30AM  
Jul-21-20 07:08PM  
Jul-07-20 10:00AM  
Jul-06-20 12:56PM  
Jul-01-20 10:47AM  
Jun-30-20 04:05PM  
Jun-19-20 09:40AM  
Jun-15-20 08:30AM  
Jun-08-20 11:24PM  
Jun-03-20 11:30AM  
May-18-20 06:23AM  
May-14-20 04:05PM  
May-13-20 01:16PM  
May-12-20 07:45AM  
May-10-20 10:46PM  
May-06-20 06:27PM  
May-05-20 02:50PM  
May-04-20 07:05PM  
Apr-27-20 04:05PM  
Apr-22-20 06:43AM  
Apr-13-20 08:31AM  
Apr-02-20 09:51AM  
Apr-01-20 08:30AM  
Mar-26-20 12:06PM  
Mar-21-20 11:30AM  
Mar-12-20 08:30AM  
Feb-25-20 06:22AM  
Feb-24-20 12:41PM  
Feb-21-20 02:25PM  
Feb-20-20 06:15PM  
Feb-19-20 12:10PM  
Feb-18-20 11:04AM  
Feb-17-20 12:30PM  
Feb-13-20 04:05PM  
Jan-30-20 04:06PM  
Jan-09-20 08:40AM  
Jan-08-20 10:18AM  
Jan-07-20 10:21AM  
Dec-31-19 07:49AM  
Dec-26-19 07:25PM  
Dec-10-19 10:46AM  
Dec-07-19 11:31AM  
Dec-04-19 07:43AM  
Nov-20-19 12:55PM  
Nov-19-19 08:51AM  
Nov-14-19 08:52AM  
Nov-08-19 10:31AM  
Nov-07-19 07:35PM  
Nov-04-19 06:51AM  
Oct-31-19 04:05PM  
Oct-27-19 02:04PM  
Oct-14-19 10:10AM  
Oct-09-19 06:11AM  
Oct-02-19 06:20PM  
Sep-18-19 08:30AM  
Sep-16-19 10:43AM  
Sep-13-19 01:54PM  
Aug-31-19 09:31AM  
Aug-29-19 06:57PM  
Aug-28-19 04:05PM  
Aug-27-19 01:05PM  
Aug-05-19 09:18AM  
Aug-03-19 12:18AM  
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant that is in Phase III clinical trial to treat patients with Cushing's syndrome; and Abraxane in combination with relacorilant, which is in Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase I/II clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator that is in Phase II for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Swisher Daniel N JRDirectorOct 19Option Exercise6.555,00032,7505,000Oct 21 09:08 PM
Swisher Daniel N JRDirectorOct 19Sale17.665,00088,3010Oct 21 09:08 PM
BAKER G LEONARD JRDirectorSep 01Buy12.5025,807322,5263,161,044Sep 01 08:26 PM
BAKER G LEONARD JRDirectorAug 28Buy12.4820,444255,2133,135,237Sep 01 08:26 PM
Swisher Daniel N JRDirectorJul 17Option Exercise6.555,00032,7505,000Jul 20 07:14 PM
Swisher Daniel N JRDirectorJul 17Sale16.485,00082,4110Jul 20 07:14 PM
BAKER G LEONARD JRDirectorMay 28Option Exercise3.4730,000104,1001,026,838May 29 04:09 PM
BAKER G LEONARD JRDirectorMay 28Sale15.7030,000471,060996,838May 29 04:09 PM
Swisher Daniel N JRDirectorMay 22Option Exercise6.555,00032,7505,000May 27 07:53 PM
MAHONEY DAVID LDirectorMay 22Option Exercise3.4738,984135,27488,984May 27 07:48 PM
Swisher Daniel N JRDirectorMay 22Sale16.105,00080,5000May 27 07:53 PM
Robb Gary CharlesChief Financial OfficerDec 09Option Exercise1.9230,00057,60038,025Dec 11 04:42 PM
Robb Gary CharlesChief Financial OfficerDec 09Sale13.7330,000412,0298,025Dec 11 04:42 PM
WILSON JAMES NDirectorOct 28Option Exercise2.30284,218653,701400,000Oct 30 05:36 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.